source
- Genmab faces steep revenue cliff as Darzalex patents expire, eyes pivotal Epkinly readoutGenmab relies heavily on Darzalex, a cancer drug co‑developed with Johnson & Johnson, which currently provides about 90% of the company’s sales. U.S. patents for Darzalex are set to expire in 2029,…
- AstraZeneca partners with Oracle to boost clinical trial patient recruitment using AIAstraZeneca announced a collaboration with data-technology firm Oracle to apply artificial-intelligence tools to clinical-trial recruitment. The non-binding agreement will let the partners explore…